faithfully translated from the Japanese edition into English, are presented here.
Introduction
The clinical criteria for assessment of response to nonsurgical treatment of gastric cancer can be categorized under six headings: patient status at the start of therapy, description of therapy, clinical therapeutic efficacy, duration of survival, adverse drug reactions, and "other features."
Patient's status at the start of therapy
(1) Performance status Grade 0-4 (According to the "WHO criteria").
(2) Concurrent disease(s) Describe the presence and name(s) of concurrent disease(s) that may influence the outcome of chemotherapy or radiation therapy.
(3) Description of lesion(s) Describe the presence of previous treatment and recurrence as well as the "stage." For measurable lesion(s), describe the size(s) and the method used for the measurement.
Description of therapy
(1) Chemotherapy (1) Name of the drug, (2) route of administration, (3) interval of administration, (4) dosage or daily dose, (5) total number of administrations, (6) total dose, (7) period of administration, (8) reason for discontinuation, (9) presence and name(s) of ad-
Foreword
The World Health Organization (WHO) criteria for the assessment of response to nonsurgical cancer treatment (Reporting Response in the WHO Handbook, 1979) have been proven to provide a durable international standard. These criteria alone, however, insufficiently assess the results of treatment in the setting of gastric cancer.
Recognizing this problem, and adhering to the principles encompassed by the WHO criteria, the Japanese Research Society for Gastric Cancer (JRSGC), in 1985, established new assessment criteria for gastric cancer, including quantitative criteria for assessing primary tumor responses. Two aspects of these criteria deserve particular emphasis: (1) the use of X-ray and endoscopic findings for the assessment of primary gastric lesions and (2) new methodology specific to diffusely infiltrating tumors. Under this JRSGC system, primary lesions were broadly classified as: (a) measurable, (b) evaluable but not measurable, and (c) diffusely infiltrating.
These criteria were revised in 1993, concurrently with the General rules for gastric cancer study. Detailed descriptions of these criteria were published in English, for an international readership, in 1995 [1] . During the 6 years since the 1993 revision, several investigators have confirmed that the overall response according to these criteria correlated with survival time. After the establishment of the Japanese Gastric Cancer Association, reorganized from the JRSGC in 1997, these Japanese response criteria were further refined [2] . These criteria,
The entire contents of this article can be downloaded as a PDF file on the website of the Japanese Gastric Cancer Association (http://1surg.kpu-m.ac.jp/jsgcr.htm), together with the first part of the Japanese Classification of Gastric Carcinoma. Reprints are not available. 
Clinical therapeutic efficacy
(1) General objective/subjective findings (Table 1) (2) Tumor response 1. Methods of measurement a. For gastric lesion(s), describe the tumor response, morphological change, and efficacy, evaluated by X-ray and/or endoscopic examinations. b. For metastatic lesion(s), measure the lesion(s) according to the "Efficacy criteria for solid tumors" (these criteria closely match the WHO criteria) published by the Japan Society for Cancer Therapy and judge the efficacy.
Evaluation method for gastric lesions a. Measurable lesions (a-lesions) (i) Two-dimensionally measurable lesions
Calculate the product of the longest diameter and the longest rectangular diameter.
Response rate ϭ (product calculated before therapy) Ϫ (product calculated after therapy) ϫ 100% (product calculated before therapy) Enlargement rate ϭ (product calculated before therapy) Ϫ (product calculated after therapy) ϫ 100% (product calculated before therapy)
Definition of response in gastric lesions
In patients with complete response (CR), partial response (PR), and no change (NC), no new lesions should appear within 4 weeks and each defined condition should last for more than 4 weeks.
Complete response (CR)
Disappearance of all tumoral lesions and no diagnosis of any cancers.
Partial response (PR) a-lesions
At least a 50% decrease in total tumor size in two-dimensional measurable lesions and at least a 30% decrease in total tumor size in onedimensional measurable lesions. b-lesions Dramatic regression: flattening on X-ray/ endoscopic examinations, which roughly corre- sponds to at least a 50% decrease in tumor size. c-lesions
In diffusely infiltrating lesions, at least 50% enlargement of the gastric lumen in the area of the lesions by X-ray examination.
No change (NC)
Insufficient decrease in a-and b-lesions and in sufficient change in c-lesions on X-ray/endoscopic findings to qualify for a PR, or findings that are the same as baseline.
Progressive disease (PD)
Exacerbation of tumor size or X-ray/endoscopic findings (at least a 25% increase in a-lesions) or the appearance of new lesions.
Minor response (MR)
Response is separately described in each of the following cases:
• PR for less than 4 weeks • In a-and b-lesions, less than 50% but more than 25% decrease in tumor size; in c-lesions enlargement of the gastric lumen lasting for 4 weeks at least but of insufficient extent to qualify from PR
Overall response
Patients with CR or PR in gastric or metastatic lesions are defined as responders for the calculation of overall response. For the total treated population, eligible cases, complete cases, or the "Full analysis set [4] " should be described.
Overall response in patients with multiple lesions
Evaluate individual response in each organ. Overall response is defined as follows: CR, CR in all organs PR, total number of CR and PR is more than that of NC NC, number of NC exceeds the total number of CR and PR PD, at least one PD in any organ, or the appearance of new lesions.
Duration of response
The following dates should be recorded for measurement of duration of response: A, date of initiation of the treatment B, date when obvious tumor regression is first observed C, date when at least 50% decrease is first observed Pretreatment (X-ray): An excavated lesion with a raised margin extending from the gastric body to the antrum Pretreatment (endoscopic findings): An excavated lesion with a raised margin and surrounding white plaques extending from the gastric body to the antrum Actual clinical examples of a-, b-, and c-lesions are shown in Figs. 1-3 , respectively.
Duration of survival
Duration of survival is measured from the date of the beginning of treatment until the date of the patient's death (in weeks). For the total treated population, eligible cases, complete cases, and a "full analysis set [4] " should be described.
(1) 50% Survival duration This is the duration in which the cumulative survival rate in the total treated population becomes 50%.
(2) Survival rates (1-to 5-year) Calculate 1-to 5-year cumulative survival rates in the total treated population (by the Kaplan-Meier method or the life-table method).
Adverse drug reactions
Describe the toxicity and severity and date of onset and duration, according to the Revised common toxicity criteria (CTC) version 2.0. 
